Outlook Therapeutics secures $18.4 million financing, extends convertible note

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. ALAR
3. SPY
4. CCH:LN
5. META
6. CCHGY
7. PRY:IM
8. PRYMY
9. SKA-B
10. PBA

Go back to Outlook Therapeutics secures $18.4 million financing, extends convertible note

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

March 16, 2026 8:05 AM EDT

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced an amendment to its existing convertible note with Avondale Capital, LLC (the Existing Note) and the issuance of a new non-convertible, unsecured note with... More